top of page

Fête & Global Leadership Award

26th Annual Fête & 2016 Global Leadership Award

The Philadelphia Chapter of 

The French-American Chamber of Commerce 

 

proudly presented

 

The 26th Annual Fête 

​

​

2016 

​

Honoring

Hervé Hoppenot 

President and Chief Executive Officer

Incyte Corporation

Thursday, June 16th, 2016

Sheraton Society Hill Hotel Ballroom

One Dock Street near 2nd & Walnut Streets

Philadelphia, PA 19106

​

Meet Our Guest of Honor

​

Hervé Hoppenot
President and Chief Executive Officer
Incyte Corporation
​

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval, and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry, and 8,000 employees in 50 countries.

​

Mr. Hoppenot joined Novartis in 2003, and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing.He started his career in 1983 with Rhone Poulenc, which later merged and went on to form Sanofi-Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School, near Paris. His wife Anne Hoppenot is the Honorary Consul of France in Princeton, NJ.

Special Thanks to Our Corporate Sponsors
Merci Beaucoup to Our  Supporters

About Incyte Corporation

​

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. World-class science and R&D drives Incyte’s business and its commitment to improving the lives of patients with cancer and other diseases. The Company’s first commercial product, Jakafi, is the first and only approved treatment for myelofibrosis [i] and polycythemia vera [ii], two rare blood cancers knows as myeloproliferative neoplasms.

​

Incyte also has a diverse and growing clinical portfolio that continues to show great progress — the Company currently has 13 development molecules against 10 different targets and through its developed products and clinical collaborations has more than 80 ongoing clinical studies, both proof-of-concept and pivotal trials. 

​

Headquartered in Wilmington, Delaware, Incyte Corporation has operations in Switzerland, France, Germany, The United Kingdom, Italy, Sweden, Spain, The Netherlands, and Austria.  The Company currently employs more than 900 people. For more information, visit www.incyte.com.

​

[i] MF is a rare blood cancer in which scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells. MF is a serious, chronic and progressive condition.

[ii] PV is a rare, chronic blood disease in which a person’s body makes too many red blood cells, and may also result in too many white blood cells or platelets. Too many red blood cells can cause the blood to thicken, leading to blood clots that block the flow of blood through the arteries and veins.

​

​

Previous Distinguished Honorees
(Formerly La Fête du Printemps Spring Gala)

​

2015    Arnaud Vaissié, Co-founder, Chairman & CEO, International SOS

2014    Dikembe Mutombo, NBA Legend & Humanitarian

2013    Tom Connelly, Chief Innovation Officer, DuPont

2012    Pierre Brondeau, President, CEO & Chairman of the Board, FMC Corporation

2011    Jean-Pierre Clamadieu, Chairman & Chief Executive Officer, Rhodia S.A. (now Solvay)

2010    Frank Baldino, Jr., Ph.D., Founder, Chairman & CEO, Cephalon Inc. (now Teva)

2009   Raj L. Gupta, Chairman & CEO, Rohm & Haas Company (now Dow Advanced Materials)

2008   Pierre Dufour, President & CEO, American Air Liquide; Sr. EVP & Director, L’Air Liquide S.A.

2007   Jean-François Phelizon, President & CEO, Saint-Gobain Corp.; SVP, Group Saint-Gobain

2006   Stephen K. Green, Group Chairman, HSBC Holdings plc

2005   Jean-François Dehecq, Chairman & CEO, Sanofi-Aventis Group

2004   Bernard Poussot, President, Wyeth Pharmaceuticals (now Pfizer)

2003   His Excellency Jean-David Levitte, Ambassador of France to the United States

2002   Jean-Pierre Loubinoux, Chairman and CEO, SNCF International

2001    Leonard A. Lauder, Chairman, The Estée Lauder Companies Inc.

2000   Robert Venturi & Denise Scott Brown, Architects and City Planners

1999    Anne d’Harnoncourt, CEO, & Joseph Rishel, Curator, Phila. Museum of Art/Rodin Museum

1998    Bruno Bonduelle, Chair & CEO, Groupe Bonduelle, President, Lille/Nord-Pas de Calais Dev.

1997    Jean-Pierre Garnier, President and COO, SmithKlineBeecham (now GlaxoSmithKline)

1996    Jean-Daniel Tordjman, Ambassador at Large for Int’l. Investment, Invest in France Mission

1995    Pierre Salinger, Consultant, Author, Journalist, Press Sec. to Presidents Kennedy & Johnson

1994    Serge Bellanger, President, FACC National & NY Chapter, EVP & General Manager, CIC, NY

1993    Madame Georges Pompidou, First Lady of France, Champion of the Elderly & Handicapped

1992    Jean-Daniel Tordjman, Minister Econ. & Comm. Affairs, Embassy of France, Washington, DC

1991    Jacques Andréani, Ambassador of France to the United States

​

​

Back to Top

​

​

​

bottom of page